RAD51 Mediates Resistance of Cancer Stem Cells to PARP Inhibition in Triple-Negative Breast Cancer
Abstract
Introduction: PARP inhibitors have shown promising results in early studies for treatment of breast cancer susceptibility gene (BRCA)–deficient breast cancers; however, resistance ultimately develops. Furthermore, the benefit of PARP inhibitors (PARPi) in triple-negative breast cancers (TNBC) remains unknown. Recent evidence indicates that in TNBCs, cells that display “cancer stem cell” properties are resistant to conventional treatments, mediate tumor metastasis, and contribute to recurrence. The sensitivity of breast cancer stem cells (CSC) to PARPi is unknown.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Jan 15, 2017
- Source ID
- 10.1158/1078-0432.ccr-15-1348
Entities
People
- Alex Fox
- April Davis
- Joey Guy
- Justin Colacino
- Li Shang
- Max S. Wicha
- Michael D. Brooks
- Monika L. Burness
- Rachel Martin-trevino
- Ramdane Harouaka
- Shawn G. Clouthier
- Shoumin Bai
- Suling Liu
- Tahra K. Luther
- Trenton L. Baker
- Yajing Liu
- Zhi-ming Shao
Organizations
- Chinese Academy of Sciences
- Fudan University
- National Natural Science Foundation of China
- Sun Yat-sen University
- Susan G. Komen for the Cure
- The Breast Cancer Research Foundation
- United States Department of Defense
- University of Science and Technology of China